Dose-restrictive and primarily myelosuppressive toxicity, as well as tumor tolerance towards alkylating compounds, mainly via the nucleotide repair enzyme MGMT (O6-methylguanine-DNA methyltransferase), are further problems associated with the successful management of brain tumors [16,17]. This evidence concerns the gene MGMT and neoplasm.